Trials / Completed
CompletedNCT00305903
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
A Prospective, 26-Week, Open-Label, Multi-Center, Single-Arm Pilot Study to Evaluate the Safety and Tolerability of Rivastigmine Capsule With Add on Memantine HCl in Patients With Probable Alzheimer's Disease (MMSE 10-20)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible patients will receive open-label treatment with rivastigmine capsules plus memantine tablets as add on therapy. This study is designed to evaluate the safety and tolerability of add on therapy with memantine to rivastigmine capsules in patients with probable AD (MMSE 10-20)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivastigmine, memantine |
Timeline
- Start date
- 2006-03-01
- Completion
- 2007-08-01
- First posted
- 2006-03-22
- Last updated
- 2007-12-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00305903. Inclusion in this directory is not an endorsement.